Anivive Lifesciences has secured a $20 million partnership with Leonid Capital Partners to further develop and commercialize its canine vaccine for Valley fever. The funding will support research programs, expand manufacturing capabilities, and drive the commercialization of their antifungal vaccine, marking a significant milestone for the company.